Dr. Fischkoff on Vision for TIL Therapy in Melanoma

Video

Steven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.

Steven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte (TIL) therapy for patients with melanoma.

In the next 5 to 10 years, there is a bright future for this type of treatment, Fischkoff explains. Although its initial focus will be in the field of melanoma, he predicts it will move into other tumor types, such as head and neck cancer.

Next steps will include modifying TILs—either chemically or genetically—in order to make them more active, he adds. Beyond this development, there will likely be clinical trials to determine whether this type of therapy is more effective alone or in combination.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD